Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adefovir dipivoxil for the treatment of chronic hepatitis B

Adefovir dipivoxil treatment results in significant histologic, virologic, and biochemical improvement in patients with chronic hepatitis B, find researchers in the latest issue of the New England Journal of Medicine.

News image

fiogf49gjkf04

Adefovir dipivoxil, a nucleotide analogue, has shown significant antiviral activity in patients with chronic hepatitis B, in phase 1 and 2 clinical trials.

In this double-blind study, a team of international researchers assessed 185 patients with chronic hepatitis B, who were negative for hepatitis B e antigen (HBeAg).

The team randomized patients to receive either 10 mg of adefovir dipivoxil or placebo once daily for 48 weeks.

The team considered that the primary end point to be histologic improvement.

At week 48, 64% of patients who had base-line liver-biopsy specimens available in the adefovir dipivoxil group had improvement in histologic liver abnormalities. This compared with 33% of patients in the placebo group.

The researchers found reductions in serum hepatitis B virus (HBV) DNA levels in the adefovir dipivoxil group. HBV DNA levels fell to less than 400 copies per ml in 51% of patients in the adefovir dipivoxil group, but in none of those in the placebo group.

They determined that the median decrease in log-transformed HBV DNA levels was greater in the adefovir dipivoxil group, than in the placebo (3.91 versus 1.35 log copies per ml).

In addition, the team found that alanine aminotransferase levels had normalized at week 48 in 72% of patients receiving adefovir dipivoxil, compared with 29% those receiving placebo.

No HBV polymerase mutations associated with resistance to adefovir were identified.

Furthermore, the safety profile of adefovir dipivoxil was similar to that of the placebo.

Dr Stephanos Hadziyannis's team concluded, "In patients with HBeAg-negative chronic hepatitis B, 48 weeks of adefovir dipivoxil treatment resulted in significant histologic, virologic, and biochemical improvement, with an adverse-event profile similar to that of placebo".

"There was no evidence of the emergence of adefovir-resistant HBV polymerase mutations."

In a related study in the same publication, a second team of researchers assessed patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg).

In this study, the research team randomly assigned 515 patients to receive 10 mg of adefovir dipivoxil, 30 mg of adefovir dipivoxil, or placebo daily for 48 weeks.

The primary end point of the study was histologic improvement in the 10-mg group.

Patients showing histologic improvement:
- 10 mg adefovir = 53%
- 30 mg adefovir = 59%
- placebo = 25%
New England Journal of Medicine

After 48 weeks of treatment, more patients who received 10 mg or 30 mg of adefovir dipivoxil, than who received placebo, had histologic improvement (53%, 59%, 25%, respectively).

In addition, patients in the adefovir dipvoxil group had a reduction in serum HBV DNA levels, undetectable levels (fewer than 400 copies per ml of serum HBV DNA, normalization of alanine aminotransferase levels, and HBeAg seroconversion.

Again, no adefovir-associated resistance mutations were identified in the HBV DNA polymerase gene.

The research team determined that the safety profile of the 10-mg dose of adefovir dipivoxil was similar to that of placebo.

However, in the 30mg group there was a higher frequency of adverse events and renal laboratory abnormalities.

Dr Patrick Marcellin's team concluded, "In patients with HBeAg-positive chronic hepatitis B, 48 weeks of 10 mg or 30 mg of adefovir dipivoxil per day resulted in histologic liver improvement, reduced serum HBV DNA and alanine aminotransferase levels, and increased the rates of HBeAg seroconversion".

"The 10-mg dose has a favorable risk-benefit profile for long-term treatment".

"No adefovir-associated resistance mutations were identified in the HBV DNA polymerase gene".

New Engl J Med 2003; 348(9): 800-7, 808-16
03 March 2003

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Adalimumab and infliximab in biologic-naÔve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohnís disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
GlecaprevirĖpibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us